Shijiazhuang Yiling Pharmaceutical
Shijiazhuang Yiling Pharmaceutical Co Ltd is a Chinese multinational pharmaceutical and biotechnology enterprise specializing in the research, development, manufacturing, and commercialization of traditional Chinese medicines (TCM), innovative botanical drugs, and Western synthetic pharmaceuticals, prominently featuring cardiovascular and respiratory medications such as Lianhua Qingwen capsules. The company operates extensive pharmaceutical manufacturing plants, traditional medicine research laboratories, and botanical extraction facilities across China. Its core business operations encompass traditional Chinese medicine production, botanical drug research, pharmaceutical synthesis, and commercial distribution. Revenue is derived primarily from the wholesale and retail sale of pharmaceutical drugs and botanical healthcare formulations. Shijiazhuang Yiling Pharmaceutical holds a leading market position in traditional Chinese medicine manufacturing and botanical drug research in China. The company is headquartered in Shijiazhuang, Hebei Province, China, and its shares trade on the Shenzhen Stock Exchange.
2 of the funds FundTelligence covers report a position in Shijiazhuang Yiling Pharmaceutical.
- Legal name
- Shijiazhuang Yiling Pharmaceutical Co Ltd
- Sector
- Health Care
- Country
- China
- Funds holding it
- 2
Funds holding Shijiazhuang Yiling Pharmaceutical
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.01 % (full portfolio disclosed, September 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, September 2026)